Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI

Nature Reviews Nephrology

Volumn 10, Issue 1, 2014, Pages 8-9

  Mikhailidis, Dimitri P ^a   Athyros, Vasilios G ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN;

ACUTE CORONARY SYNDROME; ACUTE KIDNEY FAILURE; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROPHYLAXIS;

ACUTE KIDNEY INJURY; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TIME FACTORS;

EID: 84890805839     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.249     Document Type: Article

References (11)

1. McCullough, P. A. et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am. J. Cardiol. 98, 5K-13K (2006).
2. Chang, C. F. & Lin, C. C. Current concepts of contrast-induced nephropathy: a brief review. J. Chin. Med. Assoc. http://dx.doi.org/10.1016/j. jcma.2013.08.011.
3. Han, Y. et al. Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.09. 017.
4. Leoncini, M. et al. Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome. Results from protective effect of rosuvastatin and antiplatelet.
5. therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS study). J. Am. Coll. Cardiol. http://dx.doi.org/10.1016/j.jacc.2013.04.105.
6. Ho, J. E. et al. Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the treating to new targets [TNT] study). Am. J. Cardiol. 109, 1761-1766 (2012).
7. Athyros, V. G., Karagiannis, A., Katsiki, N. & Mikhailidis, D. P. Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. Am. J. Cardiol. 110, 763 (2012).
8. Quintavalle, C. et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 126, 3008-3016 (2012).
9. Patti G. et al. Short-term, high-dose atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty-contrast-induced nephropathy] trial). Am. J. Cardiol. 108, 1-7 (2011).
10. McCullough, P. A. Contrast-induced acute kidney injury. J. Am. Coll. Cardiol. 51, 1419-1428 (2008).
11. Pasceri, V. et al. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (atorvastatin for reduction of myocardial damage during angioplasty) study. Circulation 110, 674-678 (2004).